Lupron Package Insert Information
Lupron is being used off-label by gender clinics and doctors to prevent children from entering puberty. Transgender-rights activists tell people that Lupron is perfectly safe for children. Here's what Abbvie, Lupron's maker, is obliged by law to put in Lupron's package insert.
Please note the conditions for which Lupron is approved: Central Precocious Puberty (pre-pubescent children, 1 in 5000-10,000 children), Endometriosis (adult women), Fibroids (adult women), and Prostate Cancer (adult men). Lupron has not been approved by the FDA for use in otherwise healthy gender dysphoric (transgender-identified children), but it is being used to stop puberty in exactly that population.
Highlighted below are the known side effects for the FDA approved uses of Lupron. Lupron has not been approved for gender dysphoria and has not been proven to be an effective treatment. In addition, most of these treatments are limited to fewer than twelve months of use, whereas many children with gender dysphoria are frequently treated with Lupron for three years or longer. There is no research to determine the long term side effects of Lupron, especially in children.
LUPRON PACKAGE INSERT
CHILDREN Central Precocious Puberty
MEN Prostate CancerUses1-3
LUPRON DEPOT® (leuprolide acetate for depot suspension) 3.75 mg for 1‑month and 11.25 mg for 3‑month administration are prescription medications used for the management of endometriosis, including pain relief and reduction of endometriotic lesions. LUPRON DEPOT 3.75 mg for